Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

Recently, Absci entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities. Needham analyst Gil Blum writes that Absci sets ...

Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...

About AMD For more than 50 years AMD has driven $20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct ...

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

Absci's recent strategic collaborations with Advanced Micro Devices (NASDAQ:AMD) and AstraZeneca (NASDAQ:AZN) were also spotlighted. The partnership with AMD, which includes a $20 million ...

Absci's recent strategic collaborations with Advanced Micro Devices (NASDAQ:AMD) and AstraZeneca (NASDAQ:AZN) were also spotlighted. The partnership with AMD, which includes a $20 million investment, ...